Trial Profile
Investigation on Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of NNC9204-1706 in Male Subjects Being Overweight or With Obesity
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Sep 2017
Price :
$35
*
At a glance
- Drugs NN-9423 (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 22 Sep 2017 Status changed from recruiting to completed.
- 05 Apr 2017 New trial record